ArticleNature communications2017
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.Nature genetics · 2025Pooled it
- Genetically adjusted PSA levels for prostate cancer screening.Nature medicine · 2023Pooled it
- Clinical translation of polygenic scores for prostate cancer screening.Nature reviews. Urology · 2026Review
- A large-scale multi-ancestry genome-wide association study of chronic prostatitis/chronic pelvic pain syndrome in men.Nature communications · 2026Article
- MIXED MODELING APPROACH FOR CHARACTERIZING THE GENETIC EFFECTS IN A LONGITUDINAL PHENOTYPE.The annals of applied statistics · 2025Article
- A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.Nature communications · 2024Article
- Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer.HGG advances · 2024Article
- Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.JAMA oncology · 2023Article
- Article
- Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer.medRxiv : the preprint server for health sciences · 2023Article
- Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy.Annals of medicine · 2023Review
- Age-specific percentile-based prostate-specific antigen cutoff values predict the risk of prostate cancer: A single hospital observation.BioMedicine · 2023Article
- Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa.Genome biology · 2022Article
- Polygenic scores in biomedical research.Nature reviews. Genetics · 2022Article
- Precision intervention for prostate cancer: Re-evaluating who is at risk.Cancer letters · 2022Review
- Article
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG advances · 2022Article
- Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.Scientific reports · 2022Article
- Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil.Genetics and molecular biology · 2022Article
- Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.The Prostate · 2021Article
Corrections and comments
- Commented on by
Authors and funding
29 authors at 8 institutions in 3 countries.
Thomas J HoffmannDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.
Michael N PassarelliDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.
Rebecca E GraffDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.ORCID 0000-0003-0316-8303
Nima C EmamiDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.
Lori C SakodaDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Eric JorgensonDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.ORCID 0000-0002-5829-8191
Laurel A HabelDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Jun ShanDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Dilrini K RanatungaDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Charles P QuesenberryDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Chun R ChaoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA.
Nirupa R GhaiDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA.
David AaronsonDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California 94612, USA.
Joseph PrestiDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California 94612, USA.
Tobias NordströmDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden.
Zhaoming WangLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Sonja I BerndtLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Stephen J ChanockLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Jonathan D MosleyDepartment of Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA.
Robert J KleinIcahn Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029 USA.
Mridu MiddhaIcahn Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029 USA.
Hans LiljaDepartments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Olle MelanderDepartment of Clinical Sciences, Lund University, Malmö 205 02, Sweden.
Mark N KvaleInstitute for Human Genetics, University of California San Francisco, San Francisco, California 94143, USA.
Pui-Yan KwokInstitute for Human Genetics, University of California San Francisco, San Francisco, California 94143, USA.
Catherine SchaeferDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.
Neil RischDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente, Northern California, Oakland, California 94612, USA.ORCID 0000-0002-5599-8387
John S WitteDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94158, USA.
Kaiser Permanente · USUniversity of California, San Francisco · USMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USKaiser Permanente Oakland Medical Center · USKarolinska Institutet · SELund University · SEVanderbilt University · US
Funding
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MPLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9MA Resource for Genetic Epidemiology Research in Adult Health and AgingRC2AG036607 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI RISCH, NEIL J., SCHAEFER, CATHERINE ANN · 2009 to 2010
$24.8MTargeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A. · 2015 to 2025
$19.9MVanderbilt Genome-Electronic Records ProjectU01HG004603 · NHGRI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2007 to 2011
$7.3MBMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6MTraining in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5MVESPA: Vanderbilt Electronic Systems for Pharmacogenomic AssessmentRC2GM092618 · NIGMS · VANDERBILT UNIVERSITY · PI DENNY, JOSHUA C., RODEN, DAN M · 2009 to 2010
$6.4MGenetic Epidemiology of Prostate Cancer Risk and ProgressionR01CA088164 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAN DEN EEDEN, STEPHEN K., WITTE, JOHN S. · 2000 to 2015
$6.1MGenomewide Association Study of Prostate CancerU01CA127298 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2008 to 2012
$5.1MImproving prostate cancer screening by integration of SNPs with blood biomarkersR01CA175491 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KLEIN, ROBERT J. · 2013 to 2018
$2.8MGenome-wide Pleiotropy Scan across Multiple CancersR01CA201358 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAFF, REBECCA ELIZABETH, SAKODA, LORI · 2016 to 2019
$2.5MAmerican Heart Association-American Stroke Association 16FTF30130005NCATS NIH HHS UL1 TR000445NCI NIH HHS K07 CA188142NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA088164NCI NIH HHS R01 CA175491NCI NIH HHS R01 CA201358NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA112355NCI NIH HHS U01 CA127298NHGRI NIH HHS U01 HG004603NIA NIH HHS RC2 AG036607NIGMS NIH HHS RC2 GM092618NIGMS NIH HHS T32 GM067547NIH HHS S10 OD018522
Abstract
Prostate-specific antigen (PSA) levels have been used for detection and surveillance of prostate cancer (PCa). However, factors other than PCa-such as genetics-can impact PSA. Here we present findings from a genome-wide association study (GWAS) of PSA in 28,503 Kaiser Permanente whites and 17,428 men from replication cohorts. We detect 40 genome-wide significant (P<5 × 10
Indexed as
Genetic LociPolymorphism, Single NucleotideAdultAgedAged, 80 and overAllelesAsian PeopleBiomarkers, TumorBlack PeopleGene ExpressionGene FrequencyGenome-Wide Association StudyHumansMaleMiddle AgedProstateBiomarkers, TumorProstate-Specific Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.